<DOC>
	<DOCNO>NCT00410982</DOCNO>
	<brief_summary>The goal clinical research study find high tolerate dose gemcitabine give busulfan melphalan . The safety drug combination also study .</brief_summary>
	<brief_title>Gemcitabine Plus Busulfan , Melphalan Hematopoietic Cell Transplant Advanced Lymphoid Malignancies</brief_title>
	<detailed_description>Busulfan melphalan design kill cancer cell bind DNA ( genetic material cell ) , may cause cancer cell die . They commonly use stem cell transplantation . Gemcitabine design disrupt growth cancer cell , may cause cancer cell die . It may help increase effect busulfan melphalan tumor cell , allow cell repair DNA damage cause busulfan melphalan . You apheresis do collect stem cell . Apheresis process remove part blood ( platelet white blood cell ) body order remove certain element , stem cell . Then , rest blood return back body . Your stem cell put back body finish receiving gemcitabine , busulfan , melphalan . Apheresis do major vein central venous catheter ( CVC ) , usually chest . A CVC sterile flexible tube place large vein local anesthesia . Your doctor explain procedure detail , require sign separate consent form procedure . If find eligible take part study , enrol group least 2 participant begin receive study drug . The dose study drug receive depend enrol study . If intolerable side effect occur group , researcher continue enroll participant next high dose level high tolerable dose study drug find . The dose receive remain throughout study . Before start receive chemotherapy treatment dos , give small test dose busulfan . Blood ( 1 teaspoon ) drawn check level drug blood ten different timepoints ( 5-6 tablespoon total ) . This help study staff calculate treatment dose drug . If schedule conflict laboratory available testing , procedure perform . In case , would receive unchanging dose busulfan treatment . During Day 1 receive gemcitabine busulfan CVC . On Days 2-4 , receive busulfan . On Day 5 , receive study drug . On Day 6 , receive gemcitabine follow melphalan . On Day 7 , receive melphalan . On Day 8 , receive study drug . On Day 9 , receive autologous stem cell needle vein 30-60 minute . If B-cell cancer , receive rituximab ( treatment use certain lymphomas chronic lymphocytic leukemia ) part standard care , 1 day 8 day infusion autologous cell . As part standard care , receive G-CSF ( filgrastim ) injection skin daily , start 1 day transplant , blood cell level return normal . As part standard care , receive total 6 dos palifermin vein . Three ( 3 ) dos give start chemotherapy ( 24-hour break last dose palifermin first dose chemotherapy ) , 3 dos give last chemotherapy dose , start Day 0 . You take study 100 day transplant . You may take study early disease get bad experience intolerable side effect . As part standard care , remain hospital 3-4 week transplantation . After release hospital , continue outpatient Houston area monitor infection transplant-related complication . This investigational study . Busulfan , gemcitabine , melphalan FDA approve commercially available . The use study drug together use gemcitabine dose level investigational . Up 143 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>1 . Age 18 &lt; 70 year . 2 . Patients lymphoid malignancy qualify treatment protocol high priority : 2.1 ) Primary refractory/recurrent Hodgkin 's disease 2.2 ) Primary refractory/recurrent nonHodgkin 's lymphoma 2.3 ) Multiple myeloma beyond first remission unresponsive therapy , qualify high priority melphalanbased protocol . 3 . Adequate renal function , define estimate serum creatinine clearance &gt; /= 50 ml/min and/or serum creatinine &lt; /= 1.8 mg/dL . 4 . Adequate hepatic function , define Serum glutamic oxaloacetic transaminase ( SGOT ) and/or serum glutamicpyruvic transaminase ( SGPT ) &lt; /= 3 * upper limit normal ; serum bilirubin alkaline phosphatase &lt; /= 2 * upper limit normal . 5 . Adequate pulmonary function force expiratory volume 1 second ( FEV1 ) , force vital capacity ( FVC ) Carbon Monoxide Diffusing Capacity ( DLCO ) &gt; /= 50 % expect corrected hemoglobin volume . 6 . Adequate cardiac function leave ventricular ejection fraction &gt; /= 40 % . No uncontrolled arrhythmias symptomatic cardiac disease . 7 . Zubrod performance status &lt; 2 . 8 . Patient willing participate study provide write consent . 9 . Negative Beta HCG text woman childbearing potential , define postmenopausal 12 month previous surgical sterilization 1 . Patients grade &gt; /= 3 nonhematologic toxicity previous therapy resolve grade 1 . 2 . Patients prior whole brain irradiation 3 . Patients active hepatitis B virus ( HBV ) , either active carrier ( HBsAg + ) viremic ( HBV DNA &gt; =10,000 copies/mL , &gt; = 2,000 IU/mL ) . 4 . Evidence either cirrhosis stage 34 liver fibrosis patient chronic hepatitis C positive hepatitis C serology . 5 . Active infection require parenteral antibiotic . 6 . Human immunodeficiency virus ( HIV ) infection , unless patient receive effective antiretroviral therapy undetectable viral load normal CD4 count 7 . Patients receive radiation therapy head neck ( exclude eye ) , internal organ chest , abdomen pelvis month prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Lymphoid Malignancies</keyword>
	<keyword>Hodgkin 's Disease</keyword>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>Hematopoietic Cell Transplantation</keyword>
	<keyword>Myeloma</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Busulfex</keyword>
	<keyword>Myleran</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Gemcitabine Hydrochloride</keyword>
	<keyword>Gemzar</keyword>
	<keyword>Melphalan</keyword>
	<keyword>Alkeran</keyword>
</DOC>